Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Nov;33(11):1485-9.
doi: 10.1016/j.leukres.2009.01.020. Epub 2009 Feb 24.

Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group

Martha Q Lacy  1 , Susanna Jacobus, Emily A Blood, Neil E Kay, S Vincent Rajkumar, Philip R Greipp
Affiliations
Clinical Trial

Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group

Martha Q Lacy et al. Leuk Res. 2009 Nov.

Abstract

The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of interleukin-12 (IL-12) for plateau phase multiple myeloma. Patients were initially treated with IL-12 250 ng/kg I.V. daily for 5 days every 3 weeks. The trial was modified due to toxicity after the first 16 patients. IL-12 was given 300 ng/kg subcutaneously twice weekly for 24 weeks. Of 48 eligible patients, there were 4 objective responses (8.3%), all CR. The median survival and progression-free survival were 42.8 and 11.4 months. Unacceptable grade 3 or 4 non-hematologic toxicity (31% with IL-12 subcutaneously and 63% with IL-12 intravenously) was observed.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall survival: (a) I.V. only (median f/up 57 months) and (b) SC only (median f/up 34 months).
Fig. 2
Fig. 2
Progression-free survival: (a) I.V. only and (b) SC only.
See this image and copyright information in PMC

References

    1. Anonymous Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group [see comments]. Annals of Internal Medicine. 1996;124(2):212–22. - PubMed
    1. The Myeloma Trialists’ Collaborative Group Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. British Journal of Haematology. 2001;113(4):1020–34. - PubMed
    1. Salmon SE, Crowley JJ, Balcerzak SP, et al. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. Journal of Clinical Oncology. 1998;16(3):890–6. - PubMed
    1. Ludwig H, Cohen AM, Polliack A, et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Annals of Oncology. 1995;6(5):467–76. - PubMed
    1. Shustik C. Interferon in the treatment of multiple myeloma. Cancer Control. 1998;5(3):226–34. - PubMed

Publication types